Faron Pharmaceuticals Oy (LON:FARN) Stock Passes Below Fifty Day Moving Average - Here's What Happened

Key Points

• Faron Pharmaceuticals shares fell below its 50‑day moving average (50‑day MA GBX 46.93), last trading at GBX 42.50 on volume of 107,916 shares.
• The stock is far below its 200‑day MA (GBX 124.89); the company has a market capitalization of £54.76 million and a negative P/E (-1.97), indicating it is not currently profitable.
• Faron is a clinical‑stage biopharmaceutical firm developing Clevegen (bexmarilimab), an anti‑Clever‑1 antibody aimed at switching immune suppression to activation with potential in oncology and infectious disease.

Faron Pharmaceuticals Oy (LON:FARN - ) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of GBX 46.93 and traded as low as GBX 42. Faron Pharmaceuticals Oy shares last traded at GBX 42.50, with a volume of 107,916 shares.

Faron Pharmaceuticals Oy Trading Up 3.6%

The company has a current ratio of 0.84, a quick ratio of 1.09 and a debt-to-equity ratio of -133.35. The company's fifty day moving average is GBX 46.93 and its 200-day moving average is GBX 124.89. The firm has a market capitalization of £54.76 million, a P/E ratio of -1.97 and a beta of 1.18.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.